KIR3DL1 and breast carcinoma: With the aim to develop effective NK-cell-based therapies against breast cancer, we investigated the combination of the monoclonal antibody trastuzumab and KIR-ligand-mismatched donor NK cells to improve the responses against breast cancer in an immunosuppressive environment.